Sign in
P2.44: An Update of a Pooled Analysis of Nivolumab for the Treatment of Advanced NSCLC and the Role of PD-L1 as a BIOMARKER: Track: Immunotherapy
Journal article   Open access  Peer reviewed

P2.44: An Update of a Pooled Analysis of Nivolumab for the Treatment of Advanced NSCLC and the Role of PD-L1 as a BIOMARKER: Track: Immunotherapy

Pedro Aguiar, Ramon De Mello, Ilka Santoro, Hakaru Tadokoro, Carmelia Barreto, Pedro Oliveira and Gilberto Lopes
Journal of thoracic oncology, Vol.11(10), pp.S245-S245
2016-10
PMID: 27676578
url
https://doi.org/10.1016/j.jtho.2016.08.115View
Published (Version of record) Open

Metrics

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
International collaboration
Citation topics
1 Clinical & Life Sciences
1.6 Immunology
1.6.214 PD-1
Web Of Science research areas
Oncology
Respiratory System
ESI research areas
Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Details